Cargando…
TP53 Mutation Mapping in Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study
Background: TP53 is frequently mutated in solid tumors, but its basic mutation mapping is mixed, particularly in aggressive-stage lung cancer. Experimental Design: We curated a total of 139 advanced non-small cell lung cancer (NSCLC) patients who harbored wild-type TP53 (TP53wt) or mutated TP53 (TP5...
Autores principales: | Hao, Fang, Gu, Liyan, Zhong, Diansheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599964/ https://www.ncbi.nlm.nih.gov/pubmed/36290859 http://dx.doi.org/10.3390/curroncol29100582 |
Ejemplares similares
-
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
por: Sun, Haiyan, et al.
Publicado: (2023) -
Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer
por: Fang, Shencun, et al.
Publicado: (2020) -
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013) -
Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer
por: Gu, Liyan, et al.
Publicado: (2019) -
Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)